-
1
-
-
33746455271
-
Head and neck cancer: Past, present and future
-
Chin D, Boyle GM, Porceddu S, et al. Head and neck cancer: past, present and future. Expert Rev Anticancer Ther 2006; 6: 1111-8
-
(2006)
Expert Rev Anticancer Ther
, vol.6
, pp. 1111-1118
-
-
Chin, D.1
Boyle, G.M.2
Porceddu, S.3
-
2
-
-
33846677634
-
Malignancies of the head and neck: The role for molecular targeted agents
-
Agulnik M. Malignancies of the head and neck: the role for molecular targeted agents. Expert Opin Ther Targets 2007; 11: 207-17
-
(2007)
Expert Opin Ther Targets
, vol.11
, pp. 207-217
-
-
Agulnik, M.1
-
3
-
-
33846457870
-
Cancer statistics, 2007
-
Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66
-
(2007)
CA Cancer J Clin
, vol.57
, pp. 43-66
-
-
Jemal, A.1
Siegel, R.2
Ward, E.3
-
4
-
-
0035990824
-
End points for new agents in induction chemotherapy for locally advanced head and neck cancers
-
Monnerat C, Faivre S, Temam S, et al. End points for new agents in induction chemotherapy for locally advanced head and neck cancers. Ann Oncol 2002; 13: 995-1006
-
(2002)
Ann Oncol
, vol.13
, pp. 995-1006
-
-
Monnerat, C.1
Faivre, S.2
Temam, S.3
-
5
-
-
14844321323
-
Trends in incidence and prognosis for head and neck cancer in the United States: A site-specific analysis of the SEER database
-
Carvalho AL, Nishimoto IN, Califano JA, et al. Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer 2005; 114: 806-16
-
(2005)
Int J Cancer
, vol.114
, pp. 806-816
-
-
Carvalho, A.L.1
Nishimoto, I.N.2
Califano, J.A.3
-
6
-
-
33748164404
-
Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck
-
Colevas AD. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2006; 24: 2644-52
-
(2006)
J Clin Oncol
, vol.24
, pp. 2644-2652
-
-
Colevas, A.D.1
-
7
-
-
2442655601
-
The expanding role of systemic therapy in head and neck cancer
-
Cohen EE, Lingen MW, Vokes EE. The expanding role of systemic therapy in head and neck cancer. J Clin Oncol 2004; 22: 1743-52
-
(2004)
J Clin Oncol
, vol.22
, pp. 1743-1752
-
-
Cohen, E.E.1
Lingen, M.W.2
Vokes, E.E.3
-
9
-
-
34147178690
-
The epidermal growth factor receptor (EGFR) in head and neck cancer: Its role and treatment implications
-
Zimmermann M, Zouhair A, Azria D, et al. The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications. Radiat Oncol 2006; 1: 11
-
(2006)
Radiat Oncol
, vol.1
, pp. 11
-
-
Zimmermann, M.1
Zouhair, A.2
Azria, D.3
-
11
-
-
36348987149
-
Cetuximab: A review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer
-
Blick SK, Scott LJ. Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer. Drugs 2007; 67: 2585-607
-
(2007)
Drugs
, vol.67
, pp. 2585-2607
-
-
Blick, S.K.1
Scott, L.J.2
-
12
-
-
0028929803
-
Angiogenesis in cancer, vascular, rheumatoid and other disease
-
Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31
-
(1995)
Nat Med
, vol.1
, pp. 27-31
-
-
Folkman, J.1
-
13
-
-
33745738260
-
Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: From the biology to the clinic
-
Ranieri G, Patruno R, Ruggieri E, et al. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Curr Med Chem 2006; 13: 1845-57
-
(2006)
Curr Med Chem
, vol.13
, pp. 1845-1857
-
-
Ranieri, G.1
Patruno, R.2
Ruggieri, E.3
-
14
-
-
33845874370
-
A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers
-
Fury MG, Zahalsky A, Wong R, et al. A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers. Invest New Drugs 2007; 25: 165-72
-
(2007)
Invest New Drugs
, vol.25
, pp. 165-172
-
-
Fury, M.G.1
Zahalsky, A.2
Wong, R.3
-
16
-
-
0037429725
-
The ErbB receptors and their role in cancer progression
-
Holbro T, Civenni G, Hynes NE. The ErbB receptors and their role in cancer progression. Exp Cell Res 2003; 284: 99-110
-
(2003)
Exp Cell Res
, vol.284
, pp. 99-110
-
-
Holbro, T.1
Civenni, G.2
Hynes, N.E.3
-
17
-
-
0034788982
-
The ErbB receptor tyrosine family as signal integrators
-
Hynes NE, Horsch K, Olayioye MA, et al. The ErbB receptor tyrosine family as signal integrators. Endocr Relat Cancer 2001; 8: 151-9
-
(2001)
Endocr Relat Cancer
, vol.8
, pp. 151-159
-
-
Hynes, N.E.1
Horsch, K.2
Olayioye, M.A.3
-
19
-
-
18644386251
-
Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains
-
Ogiso H, Ishitani R, Nureki O, et al. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 2002; 110: 775-87
-
(2002)
Cell
, vol.110
, pp. 775-787
-
-
Ogiso, H.1
Ishitani, R.2
Nureki, O.3
-
20
-
-
0037145061
-
Ligand-induced, receptor-mediated dimerization and activation of EGF receptor
-
Schlessinger J. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 2002; 110: 669-72
-
(2002)
Cell
, vol.110
, pp. 669-672
-
-
Schlessinger, J.1
-
22
-
-
0141542627
-
Distinct mechanisms mediate the initial and sustained phases of cell migration in epidermal growth factor receptor-overexpressing cells
-
Kruger JS, Reddy KB. Distinct mechanisms mediate the initial and sustained phases of cell migration in epidermal growth factor receptor-overexpressing cells. Mol Cancer Res 2003; 1: 801-9
-
(2003)
Mol Cancer Res
, vol.1
, pp. 801-809
-
-
Kruger, J.S.1
Reddy, K.B.2
-
23
-
-
0036235654
-
The roles of JNK1 and Stat3 in the response of head and neck cancer cell lines to combined treatment with all-trans-retinoic acid and 5-fluorouracil
-
Masuda M, Toh S, Koike K, et al. The roles of JNK1 and Stat3 in the response of head and neck cancer cell lines to combined treatment with all-trans-retinoic acid and 5-fluorouracil. Jpn J Cancer Res 2002; 93: 329-39
-
(2002)
Jpn J Cancer Res
, vol.93
, pp. 329-339
-
-
Masuda, M.1
Toh, S.2
Koike, K.3
-
24
-
-
0036632368
-
The phosphatidylinositol 3-Kinase AKT pathway in human cancer
-
Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501
-
(2002)
Nat Rev Cancer
, vol.2
, pp. 489-501
-
-
Vivanco, I.1
Sawyers, C.L.2
-
25
-
-
0035266290
-
Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association
-
Ellerbroek SM, Halbleib JM, Benavidez M, et al. Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association. Cancer Res 2001; 61: 1855-61
-
(2001)
Cancer Res
, vol.61
, pp. 1855-1861
-
-
Ellerbroek, S.M.1
Halbleib, J.M.2
Benavidez, M.3
-
26
-
-
0037329054
-
The role of ubiquitylation in signaling by growth factors: Implications to cancer
-
Shtiegman K, Yarden Y. The role of ubiquitylation in signaling by growth factors: implications to cancer. Semin Cancer Biol 2003; 13: 29-40
-
(2003)
Semin Cancer Biol
, vol.13
, pp. 29-40
-
-
Shtiegman, K.1
Yarden, Y.2
-
27
-
-
0036362221
-
Epidermal growth factor receptor dependence in human tumors: More than just expression?
-
Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 2002; 7 Suppl. 4: 31-9
-
(2002)
Oncologist
, vol.7
, Issue.SUPPL. 4
, pp. 31-39
-
-
Arteaga, C.L.1
-
28
-
-
33847622161
-
Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer
-
Cruz JJ, Ocana A, Del Barco E, et al. Targeting receptor tyrosine kinases and their signal transduction routes in head and neck cancer. Ann Oncol 2007; 18: 421-30
-
(2007)
Ann Oncol
, vol.18
, pp. 421-430
-
-
Cruz, J.J.1
Ocana, A.2
Del Barco, E.3
-
29
-
-
34748831698
-
Biology of interactions: Antiepidermal growth factor receptor agents
-
Harari PM, Allen GW, Bonner JA. Biology of interactions: antiepidermal growth factor receptor agents. J Clin Oncol 2007; 25: 4057-65
-
(2007)
J Clin Oncol
, vol.25
, pp. 4057-4065
-
-
Harari, P.M.1
Allen, G.W.2
Bonner, J.A.3
-
30
-
-
0021363327
-
Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies
-
Masui H, Kawamoto T, Sato JD, et al. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1984; 44: 1002-7
-
(1984)
Cancer Res
, vol.44
, pp. 1002-1007
-
-
Masui, H.1
Kawamoto, T.2
Sato, J.D.3
-
31
-
-
0035254521
-
Head and neck cancer as a clinical model for molecular targeting of therapy: Combining EGFR blockade with radiation
-
Harari PM, Huang SM. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation. Int J Radiat Oncol Biol Phys 2001; 49: 427-33
-
(2001)
Int J Radiat Oncol Biol Phys
, vol.49
, pp. 427-433
-
-
Harari, P.M.1
Huang, S.M.2
-
32
-
-
0033966576
-
In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody
-
Milas L, Mason K, Hunter N, et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 2000; 6: 701-8
-
(2000)
Clin Cancer Res
, vol.6
, pp. 701-708
-
-
Milas, L.1
Mason, K.2
Hunter, N.3
-
33
-
-
19244366949
-
Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin
-
Baselga J, Pfister D, Cooper MR, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000; 18: 904-14
-
(2000)
J Clin Oncol
, vol.18
, pp. 904-914
-
-
Baselga, J.1
Pfister, D.2
Cooper, M.R.3
-
34
-
-
32144433159
-
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
-
Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-78
-
(2006)
N Engl J Med
, vol.354
, pp. 567-578
-
-
Bonner, J.A.1
Harari, P.M.2
Giralt, J.3
-
35
-
-
33644971314
-
Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: A pilot phase II study of a new combined-modality paradigm
-
Pfister DG, Su YB, Kraus DH, et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. J Clin Oncol 2006; 24: 1072-8
-
(2006)
J Clin Oncol
, vol.24
, pp. 1072-1078
-
-
Pfister, D.G.1
Su, Y.B.2
Kraus, D.H.3
-
36
-
-
47349101706
-
Cetuximab (C-mab) and chemo-radiation (CT-RT) for loco-regional advanced squamous cell carcinoma of the head and neck (HNC): A phase II study [abstract]
-
Merlano MC, Numico G, Russi EG, et al. Cetuximab (C-mab) and chemo-radiation (CT-RT) for loco-regional advanced squamous cell carcinoma of the head and neck (HNC): a phase II study [abstract]. J Clin Oncol 2007; 25: 6043
-
(2007)
J Clin Oncol
, vol.25
, pp. 6043
-
-
Merlano, M.C.1
Numico, G.2
Russi, E.G.3
-
37
-
-
38149123171
-
Phase II evaluation of cetuximab (C225) combined with induction paclitaxel and carboplatin followed by C225, paclitaxel, carboplatin, and radiation for stage III/IV operable squamous cancer of the head and neck (ECOG, E2303) [abstract]
-
Wanebo HJ, Ghebremichael M, Burtness B, et al. Phase II evaluation of cetuximab (C225) combined with induction paclitaxel and carboplatin followed by C225, paclitaxel, carboplatin, and radiation for stage III/IV operable squamous cancer of the head and neck (ECOG, E2303) [abstract]. J Clin Oncol 2007; 25: 6015
-
(2007)
J Clin Oncol
, vol.25
, pp. 6015
-
-
Wanebo, H.J.1
Ghebremichael, M.2
Burtness, B.3
-
38
-
-
33144461661
-
Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An Eastern Cooperative Oncology Group study
-
Burtness B, Goldwasser MA, Flood W, et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005; 23: 8646-54
-
(2005)
J Clin Oncol
, vol.23
, pp. 8646-8654
-
-
Burtness, B.1
Goldwasser, M.A.2
Flood, W.3
-
39
-
-
36048934209
-
Cetuximab extends survival of patients with recurrent or metastatic SCCHN when added to first line platinum based therapy: Results of a randomized phase III (Extreme) study [abstract]
-
Vermorken J, Mesia R, Vega V, et al. Cetuximab extends survival of patients with recurrent or metastatic SCCHN when added to first line platinum based therapy: results of a randomized phase III (Extreme) study [abstract]. J Clin Oncol 2007; 25: 6091
-
(2007)
J Clin Oncol
, vol.25
, pp. 6091
-
-
Vermorken, J.1
Mesia, R.2
Vega, V.3
-
40
-
-
34250180582
-
Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy
-
Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007; 25: 2171-7
-
(2007)
J Clin Oncol
, vol.25
, pp. 2171-2177
-
-
Vermorken, J.B.1
Trigo, J.2
Hitt, R.3
-
41
-
-
23844523253
-
Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck
-
Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23: 5568-77
-
(2005)
J Clin Oncol
, vol.23
, pp. 5568-5577
-
-
Baselga, J.1
Trigo, J.M.2
Bourhis, J.3
-
42
-
-
24944490558
-
Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck
-
Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23: 5578-87
-
(2005)
J Clin Oncol
, vol.23
, pp. 5578-5587
-
-
Herbst, R.S.1
Arquette, M.2
Shin, D.M.3
-
43
-
-
34147140250
-
Induction chemotherapy (CT) with weekly paclitaxel, carboplatin, and cetuximab for squamous cell carcinoma of the head and neck (HN) [abstract]
-
Kies MS, Garden AS, Holsinger C, et al. Induction chemotherapy (CT) with weekly paclitaxel, carboplatin, and cetuximab for squamous cell carcinoma of the head and neck (HN) [abstract]. J Clin Oncol 2006; 24: 5520
-
(2006)
J Clin Oncol
, vol.24
, pp. 5520
-
-
Kies, M.S.1
Garden, A.S.2
Holsinger, C.3
-
44
-
-
0035117355
-
Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy
-
Yang XD, Jia XC, Corvalan JR, et al. Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. Crit Rev Oncol Hematol 2001; 38: 17-23
-
(2001)
Crit Rev Oncol Hematol
, vol.38
, pp. 17-23
-
-
Yang, X.D.1
Jia, X.C.2
Corvalan, J.R.3
-
45
-
-
10744221013
-
Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody
-
Foon KA, Yang XD, Weiner LM, et al. Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody. Int J Radiat Oncol Biol Phys 2004; 58: 984-90
-
(2004)
Int J Radiat Oncol Biol Phys
, vol.58
, pp. 984-990
-
-
Foon, K.A.1
Yang, X.D.2
Weiner, L.M.3
-
46
-
-
0026094165
-
Humanization of a mouse monoclonal antibody by CDR-grafting: The importance of framework residues on loop conformation
-
Kettleborough CA, Saldanha J, Heath VJ, et al. Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation. Protein Eng 1991; 4: 773-83
-
(1991)
Protein Eng
, vol.4
, pp. 773-783
-
-
Kettleborough, C.A.1
Saldanha, J.2
Heath, V.J.3
-
47
-
-
17844391092
-
Uptake of the anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 in tumors of subjects with head and neck squamous cell carcinoma (HNSCC) [abstract]
-
Hoffend J, Mohammed A, Eisenhut M, et al. Uptake of the anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 in tumors of subjects with head and neck squamous cell carcinoma (HNSCC) [abstract]. J Clin Oncol 2004; 22: 3043
-
(2004)
J Clin Oncol
, vol.22
, pp. 3043
-
-
Hoffend, J.1
Mohammed, A.2
Eisenhut, M.3
-
48
-
-
2442704412
-
Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients
-
Crombet T, Osorio M, Cruz T, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 2004; 22: 1646-54
-
(2004)
J Clin Oncol
, vol.22
, pp. 1646-1654
-
-
Crombet, T.1
Osorio, M.2
Cruz, T.3
-
49
-
-
49149084888
-
-
ClinicalTrials.gov. Phase II study of nimotuzumab and cisplatin/radiotherapy for locally advanced head and neck squamous cell cancer [online]. Available from URL: http://www.clinicaltrials.gov/ct2/show/NCT00702481 [Accessed 2008 Jul 10]
-
ClinicalTrials.gov. Phase II study of nimotuzumab and cisplatin/radiotherapy for locally advanced head and neck squamous cell cancer [online]. Available from URL: http://www.clinicaltrials.gov/ct2/show/NCT00702481 [Accessed 2008 Jul 10]
-
-
-
-
50
-
-
1842772526
-
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck
-
Soulieres D, Senzer NN, Vokes EE, et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004; 22: 77-85
-
(2004)
J Clin Oncol
, vol.22
, pp. 77-85
-
-
Soulieres, D.1
Senzer, N.N.2
Vokes, E.E.3
-
51
-
-
0032695910
-
Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: Dynamics of receptor inhibition in situ and antitumor effects in athymic mice
-
Pollack VA, Savage DM, Baker DA, et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358,774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J Pharmacol Exp Ther 1999; 291: 739-48
-
(1999)
J Pharmacol Exp Ther
, vol.291
, pp. 739-748
-
-
Pollack, V.A.1
Savage, D.M.2
Baker, D.A.3
-
52
-
-
34250208469
-
Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: A Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study
-
Siu LL, Soulieres D, Chen EX, et al. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol 2007; 25: 2178-83
-
(2007)
J Clin Oncol
, vol.25
, pp. 2178-2183
-
-
Siu, L.L.1
Soulieres, D.2
Chen, E.X.3
-
53
-
-
34250195788
-
Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib
-
Agulnik M, da Cunha Santos G, Hedley D, et al. Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib. J Clin Oncol 2007; 25: 2184-90
-
(2007)
J Clin Oncol
, vol.25
, pp. 2184-2190
-
-
Agulnik, M.1
da Cunha Santos, G.2
Hedley, D.3
-
54
-
-
41949113428
-
Final results of a phase II study of erlotinib, docetaxel and cisplatin in patients with recurrent/metastatic head and neck cancer [abstract]
-
Kim ES, Kies MS, Glisson BS, et al. Final results of a phase II study of erlotinib, docetaxel and cisplatin in patients with recurrent/metastatic head and neck cancer [abstract]. J Clin Onc 2007; 25: 6013
-
(2007)
J Clin Onc
, vol.25
, pp. 6013
-
-
Kim, E.S.1
Kies, M.S.2
Glisson, B.S.3
-
55
-
-
20144376211
-
A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group
-
Goss G, Hirte H, Miller Jr WH, et al. A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group. Invest New Drugs 2005; 23: 147-55
-
(2005)
Invest New Drugs
, vol.23
, pp. 147-155
-
-
Goss, G.1
Hirte, H.2
Miller Jr, W.H.3
-
56
-
-
3242658931
-
Development of the novel biologically targeted anticancer agent gefitinib: Determining the optimum dose for clinical efficacy
-
Wolf M, Swaisland H, Averbuch S. Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy. Clin Cancer Res 2004; 10: 4607-13
-
(2004)
Clin Cancer Res
, vol.10
, pp. 4607-4613
-
-
Wolf, M.1
Swaisland, H.2
Averbuch, S.3
-
57
-
-
36849051467
-
Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer
-
Chen C, Kane M, Song J, et al. Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer. J Clin Oncol 2007; 25: 4880-6
-
(2007)
J Clin Oncol
, vol.25
, pp. 4880-4886
-
-
Chen, C.1
Kane, M.2
Song, J.3
-
58
-
-
0037674062
-
Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck
-
Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003; 21: 1980-7
-
(2003)
J Clin Oncol
, vol.21
, pp. 1980-1987
-
-
Cohen, E.E.1
Rosen, F.2
Stadler, W.M.3
-
59
-
-
28544432807
-
Phase II trial of gefitinib 250mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
-
Cohen EE, Kane MA, List MA, et al. Phase II trial of gefitinib 250mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 2005; 11: 8418-24
-
(2005)
Clin Cancer Res
, vol.11
, pp. 8418-8424
-
-
Cohen, E.E.1
Kane, M.A.2
List, M.A.3
-
60
-
-
29144471675
-
Clinical and molecular phase II study of gefitinib in patients (pts) with recurrent squamous cell cancer of the head and neck (H&N Ca) [abstract]
-
Wheeler RH, Jones D, Sharma P, et al. Clinical and molecular phase II study of gefitinib in patients (pts) with recurrent squamous cell cancer of the head and neck (H&N Ca) [abstract]. J Clin Oncol 2005; 23: 5531
-
(2005)
J Clin Oncol
, vol.23
, pp. 5531
-
-
Wheeler, R.H.1
Jones, D.2
Sharma, P.3
-
61
-
-
31344471197
-
Preliminary results of a phase II study to evaluate gefitinib combined with docetaxel and cisplatin in patients with recurrent and/or metastatic squamous-cell carcinoma of the head and neck [abstract]
-
Belón J, Irigoyen A, Rodríguez I, et al. Preliminary results of a phase II study to evaluate gefitinib combined with docetaxel and cisplatin in patients with recurrent and/or metastatic squamous-cell carcinoma of the head and neck [abstract]. J Clin Oncol 2005; 23: 5563
-
(2005)
J Clin Oncol
, vol.23
, pp. 5563
-
-
Belón, J.1
Irigoyen, A.2
Rodríguez, I.3
-
62
-
-
34548533134
-
Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands
-
Agulnik M, Cohen EW, Cohen RB, et al. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol 2007; 25: 3978-84
-
(2007)
J Clin Oncol
, vol.25
, pp. 3978-3984
-
-
Agulnik, M.1
Cohen, E.W.2
Cohen, R.B.3
-
63
-
-
33748636081
-
A phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) [abstract]
-
Abidoye OO, Cohen EE, Wong SJ, et al. A phase II study of lapatinib (GW572016) in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) [abstract]. J Clin Oncol 2006; 24: 5568
-
(2006)
J Clin Oncol
, vol.24
, pp. 5568
-
-
Abidoye, O.O.1
Cohen, E.E.2
Wong, S.J.3
-
64
-
-
34147155082
-
A phase I, open label study ( EGF 100262) of lapatinib plus chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) [abstract]
-
Bourhis J, Harrington K, Rosine D, et al. A phase I, open label study ( EGF 100262) of lapatinib plus chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) [abstract]. Ann Oncol 2006; 17 (9s): 180
-
(2006)
Ann Oncol
, vol.17
, Issue.9 S
, pp. 180
-
-
Bourhis, J.1
Harrington, K.2
Rosine, D.3
-
65
-
-
49149113323
-
-
ClinicalTrials.gov. Lapatinib versus placebo given concurrently with cisplatin and radiotherapy in patients with head and neck cancer [online]. Available from URL: http://www.clinicaltrials.gov/ct2/show/NCT00387127 [Accessed 2008 Jul 10]
-
ClinicalTrials.gov. Lapatinib versus placebo given concurrently with cisplatin and radiotherapy in patients with head and neck cancer [online]. Available from URL: http://www.clinicaltrials.gov/ct2/show/NCT00387127 [Accessed 2008 Jul 10]
-
-
-
-
66
-
-
25144496041
-
The IGF-1 receptor and its contributions to metastatic tumor growth-novel approaches to the inhibition of IGF-1R function
-
Bahr C, Groner B. The IGF-1 receptor and its contributions to metastatic tumor growth-novel approaches to the inhibition of IGF-1R function. Growth Factors 2005; 23: 1-14
-
(2005)
Growth Factors
, vol.23
, pp. 1-14
-
-
Bahr, C.1
Groner, B.2
-
67
-
-
0033906634
-
Structure and function of the type 1 insulin-like growth factor receptor
-
Adams TE, Epa VC, Garrett TP, et al. Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci 2000; 57: 1050-93
-
(2000)
Cell Mol Life Sci
, vol.57
, pp. 1050-1093
-
-
Adams, T.E.1
Epa, V.C.2
Garrett, T.P.3
-
68
-
-
34547107855
-
Insulin-like growth factor receptor as a therapeutic target in head and neck cancer
-
Barnes CJ, Ohshiro K, Rayala SK, et al. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer. Clin Cancer Res 2007; 13: 4291-9
-
(2007)
Clin Cancer Res
, vol.13
, pp. 4291-4299
-
-
Barnes, C.J.1
Ohshiro, K.2
Rayala, S.K.3
-
70
-
-
21244493635
-
Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling
-
Mitsiades CS, Mitsiades N. Treatment of hematologic malignancies and solid tumors by inhibiting IGF receptor signaling. Expert Rev Anticancer Ther 2005; 5: 487-99
-
(2005)
Expert Rev Anticancer Ther
, vol.5
, pp. 487-499
-
-
Mitsiades, C.S.1
Mitsiades, N.2
-
71
-
-
34249748693
-
Role of insulin-like growth factor 1 receptor signalling in cancer
-
Larsson O, Girnita A, Girnita L. Role of insulin-like growth factor 1 receptor signalling in cancer. Br J Cancer 2007; 96 Suppl.: R2-6
-
(2007)
Br J Cancer
, vol.96
, Issue.SUPPL.
-
-
Larsson, O.1
Girnita, A.2
Girnita, L.3
-
72
-
-
49149094194
-
-
ClinicalTrials.gov. Phase 1 study of BIIB022 (anti-IGF-1R monoclonal antibody) in relapsed/refractory solid tumors [online]. Available from URL: http://www.clinicaltrials.gov/ct2/show/NCT00555724 [Accessed 2008 Jul 10]
-
ClinicalTrials.gov. Phase 1 study of BIIB022 (anti-IGF-1R monoclonal antibody) in relapsed/refractory solid tumors [online]. Available from URL: http://www.clinicaltrials.gov/ct2/show/NCT00555724 [Accessed 2008 Jul 10]
-
-
-
-
73
-
-
0025141337
-
What is the evidence that tumors are angiogenesis dependent?
-
Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6
-
(1990)
J Natl Cancer Inst
, vol.82
, pp. 4-6
-
-
Folkman, J.1
-
74
-
-
34548850080
-
Molecular design and clinical development of VEGFR kinase inhibitors
-
Zhong H, Bowen JP. Molecular design and clinical development of VEGFR kinase inhibitors. Curr Top Med Chem 2007; 7: 1379-93
-
(2007)
Curr Top Med Chem
, vol.7
, pp. 1379-1393
-
-
Zhong, H.1
Bowen, J.P.2
-
75
-
-
0029006696
-
Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice
-
Shalaby F, Rossant J, Yamaguchi TP, et al. Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 1995; 376: 62-6
-
(1995)
Nature
, vol.376
, pp. 62-66
-
-
Shalaby, F.1
Rossant, J.2
Yamaguchi, T.P.3
-
76
-
-
14644411058
-
Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: A meta-analysis
-
Kyzas PA, Cunha IW, Ioannidis JP. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin Cancer Res 2005; 11: 1434-40
-
(2005)
Clin Cancer Res
, vol.11
, pp. 1434-1440
-
-
Kyzas, P.A.1
Cunha, I.W.2
Ioannidis, J.P.3
-
77
-
-
16444373306
-
Potential autocrine function of vascular endothelial growth factor in head and neck cancer via vascular endothelial growth factor receptor-2
-
Kyzas PA, Stefanou D, Batistatou A, et al. Potential autocrine function of vascular endothelial growth factor in head and neck cancer via vascular endothelial growth factor receptor-2. Mod Pathol 2005; 18: 485-94
-
(2005)
Mod Pathol
, vol.18
, pp. 485-494
-
-
Kyzas, P.A.1
Stefanou, D.2
Batistatou, A.3
-
78
-
-
44649195401
-
Randomized phase II study of concomitant chemoradiotherapy with 5-fluorouracil-hydroxyurea (FHX) compared to FHX and bevazicumab (BFHX) in intermediate stage head and neck cancer (HNC) [abstract]
-
Choong NW, Haraf DJ, Cohen EE, et al. Randomized phase II study of concomitant chemoradiotherapy with 5-fluorouracil-hydroxyurea (FHX) compared to FHX and bevazicumab (BFHX) in intermediate stage head and neck cancer (HNC) [abstract]. J Clin Oncol 2007; 25: 6043
-
(2007)
J Clin Oncol
, vol.25
, pp. 6043
-
-
Choong, N.W.1
Haraf, D.J.2
Cohen, E.E.3
-
79
-
-
36048982710
-
Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell cancer of the head and neck (SCCHN) [abstract]
-
Savvides P, Greskovich J, Bokar J, et al. Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell cancer of the head and neck (SCCHN) [abstract]. J Clin Oncol 2007; 25: 6068
-
(2007)
J Clin Oncol
, vol.25
, pp. 6068
-
-
Savvides, P.1
Greskovich, J.2
Bokar, J.3
-
80
-
-
36049031069
-
Phase II trial of pemetrexed (P) and bevacizumab (B) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC): An interim analysis [abstract]
-
Karamouzis MV, Friedland D, Johnson R, et al. Phase II trial of pemetrexed (P) and bevacizumab (B) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC): an interim analysis [abstract]. J Clin Oncol 2007; 25: 6049
-
(2007)
J Clin Oncol
, vol.25
, pp. 6049
-
-
Karamouzis, M.V.1
Friedland, D.2
Johnson, R.3
-
81
-
-
51349157966
-
pKDR/KDR ratio predicts response in a phase I/II pharmacodynamic study of erlotinib and bevacizumab for recurrent or metastatic head and neck cancer (HNC) [abstract]
-
Seiwert TY, Davis DW, Yan D, et al. pKDR/KDR ratio predicts response in a phase I/II pharmacodynamic study of erlotinib and bevacizumab for recurrent or metastatic head and neck cancer (HNC) [abstract]. J Clin Oncol 2007; 25: 6021
-
(2007)
J Clin Oncol
, vol.25
, pp. 6021
-
-
Seiwert, T.Y.1
Davis, D.W.2
Yan, D.3
-
82
-
-
36048978575
-
A phase II trial of sorafenib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC): A Southwest Oncology Group (SWOG) trial [abstract]
-
Williamson SK, Moon J, Huang CH, et al. A phase II trial of sorafenib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC): a Southwest Oncology Group (SWOG) trial [abstract]. J Clin Oncol 2007; 25: 6044
-
(2007)
J Clin Oncol
, vol.25
, pp. 6044
-
-
Williamson, S.K.1
Moon, J.2
Huang, C.H.3
-
83
-
-
34548504810
-
Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma
-
Elser C, Siu LL, Winquist E, et al. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 2007; 25: 3766-73
-
(2007)
J Clin Oncol
, vol.25
, pp. 3766-3773
-
-
Elser, C.1
Siu, L.L.2
Winquist, E.3
-
84
-
-
34347333556
-
Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: Antitumour supra-additive effects on human head and neck cancer xenografts
-
Bozec A, Formento P, Lassalle S, et al. Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: antitumour supra-additive effects on human head and neck cancer xenografts. Br J Cancer 2007; 97: 65-72
-
(2007)
Br J Cancer
, vol.97
, pp. 65-72
-
-
Bozec, A.1
Formento, P.2
Lassalle, S.3
-
85
-
-
49149119386
-
-
ClinicalTrials.gov. The effects of AZD2171 & gefitinib in patients with non-small cell lung cancer or head & neck cancer [online]. Available from URL: http://www.clinicaltrials.gov/ct2/show/NCT00243347 [Accessed 2008 Jul 10]
-
ClinicalTrials.gov. The effects of AZD2171 & gefitinib in patients with non-small cell lung cancer or head & neck cancer [online]. Available from URL: http://www.clinicaltrials.gov/ct2/show/NCT00243347 [Accessed 2008 Jul 10]
-
-
-
-
86
-
-
33845789166
-
Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer
-
Bianco C, Giovannetti E, Ciardiello F, et al. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer. Clin Cancer Res 2006; 12: 7099-107
-
(2006)
Clin Cancer Res
, vol.12
, pp. 7099-7107
-
-
Bianco, C.1
Giovannetti, E.2
Ciardiello, F.3
-
87
-
-
33947732141
-
Antitumor effects of ZD6474 on head and neck squamous cell carcinoma
-
Sano D, Kawakami M, Fujita K, et al. Antitumor effects of ZD6474 on head and neck squamous cell carcinoma. Oncol Rep 2007; 17: 289-95
-
(2007)
Oncol Rep
, vol.17
, pp. 289-295
-
-
Sano, D.1
Kawakami, M.2
Fujita, K.3
|